Stayble Therapeutics AB (STABL) - Total Liabilities
Based on the latest financial reports, Stayble Therapeutics AB (STABL) has total liabilities worth Skr1.70 Million SEK (≈ $182.84K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Stayble Therapeutics AB (STABL) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Stayble Therapeutics AB - Total Liabilities Trend (2016–2025)
This chart illustrates how Stayble Therapeutics AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Stayble Therapeutics AB assets under control.
Stayble Therapeutics AB Competitors by Total Liabilities
The table below lists competitors of Stayble Therapeutics AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sky Gold Corp
V:SKYG
|
Canada | CA$385.92K |
|
Ausmon Resources Ltd
AU:AOA
|
Australia | AU$1.56 Million |
|
Rainbow Polikarbonat Sanayi Ticaret AS
IS:RNPOL
|
Turkey | TL1.38 Billion |
|
Moab Minerals Ltd
AU:MOM
|
Australia | AU$2.34 Million |
|
FDM Group Holdings PLC
LSE:FDM
|
UK | GBX37.56 Million |
|
Bohra Industries Limited
NSE:BOHRAIND
|
India | Rs62.65 Million |
|
Nexoptic Technology Corp
V:NXO
|
Canada | CA$2.25 Million |
|
Moovly Media Inc
V:MVY
|
Canada | CA$5.00 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Stayble Therapeutics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See STABL net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Stayble Therapeutics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Stayble Therapeutics AB (2016–2025)
The table below shows the annual total liabilities of Stayble Therapeutics AB from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr1.70 Million ≈ $182.84K |
-28.73% |
| 2024-12-31 | Skr2.38 Million ≈ $256.56K |
-54.11% |
| 2023-12-31 | Skr5.19 Million ≈ $559.06K |
+34.38% |
| 2022-12-31 | Skr3.87 Million ≈ $416.03K |
+0.90% |
| 2021-12-31 | Skr3.83 Million ≈ $412.32K |
+56.50% |
| 2020-12-31 | Skr2.45 Million ≈ $263.46K |
-75.55% |
| 2019-12-31 | Skr10.01 Million ≈ $1.08 Million |
+429.62% |
| 2018-12-31 | Skr1.89 Million ≈ $203.49K |
+55.95% |
| 2017-12-31 | Skr1.21 Million ≈ $130.48K |
+10.22% |
| 2016-12-31 | Skr1.10 Million ≈ $118.39K |
-- |
About Stayble Therapeutics AB
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.